Problems in vaccine development

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Volumn 33, Issue 3, 2014, Pages 166-167

  Plotkin, Stanley A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; DENGUE VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MUMPS VACCINE; NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; VACCINE; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; DRUG DEVELOPMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL MEMORY; INNATE IMMUNITY; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS ENVELOPE; BIOLOGICAL MODEL; IMMUNOLOGY; PROCEDURES;

DRUG DISCOVERY; HUMANS; IMMUNOLOGIC MEMORY; MODELS, IMMUNOLOGICAL; VIRAL VACCINES;

EID: 84902688779     PISSN: None     EISSN: 21679436     Source Type: Journal    
DOI: 10.1089/mab.2014.0011     Document Type: Article

References (13)

1. Koprowski H, Jervis GA, and Norton TW: Immune responses in human volunteers upon oral administration of a rodent-Adapted strain of poliomyelitis virus. Am J Hyg 1952;55(1):108-124.
2. Plotkin SA, Cornfeld D, and Ingalls TH: Studies of immunization with living rubella virus. Trials in children with a strain cultured from an aborted fetus. Am J Dis Child 1965;110(4):381-389.
3. Haynes BF, Gilbert PB, McElrath MJ, et al: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366(14):1275-1286.
4. Bonsignori M, Pollara J, Moody MA, et al: Antibodydependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012; 86(21):11521-11532.
5. Jegaskanda S, Weinfurter JT, Friedrich TC, and Kent SJ: Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J Virol 2013;87(10):5512-5522.
6. Robinson HL: Non-neutralizing antibodies in prevention of HIV infection. Expert Opin Biol Ther 2013;13(2):197-207.
7. Vieillard V, Strominger JL, and Debre P: NK cytotoxicity against CD4 + T cells during HIV-1 infection: A gp41 peptide induces the expression of an NKp44 ligand. Proc Natl Acad Sci USA 2005;102(31):10981-10986. (Pubitemid 41105979)
8. Sabchareon A, Wallace D, Sirivichayakul C, et al: Protective efficacy of the recombinant, live-Attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet 2012;380(9853): 1559-1567.
9. Rey FA: Dengue virus: Two hosts, two structures. Nature 2013;497(7450):443-444.
10. Plotkin SA: Is there a formula for an effective CMV vaccine? J Clin Virol 2002;25 (Suppl 2):S13-S21.
11. Misegades LK, Winter K, Harriman K, et al: Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012;308(20):2126-2132.
12. Latner DR, McGrew M, Williams N, et al: Enzyme-linked immunospot assay detection of mumps-specific antibodysecreting B cells as an alternative method of laboratory diagnosis. Clin Vaccine Immunol 2011;18(1):35-42.
13. Koprowski H, and Plotkin SA: History of Koprowski vaccine against poliomyelitis. In: History of Vaccine Development. Plotkin SA, Ed. New York, Springer, 2011, pp. 155-166.